Evidence map›Paper›PMID 29429421›Full record

ArticleEpidemiology and infection2018

Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population.

M A Fill, L A Sizemore, M Rickles, K C Cooper, C M Buecker, H L Mullins, M G Hofmeister, W E Abara, M A Foster, A K Asher and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Epidemiology and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. [Seroprevalence and risk factor for hepatitis C in Nogales, Sonora].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

M A FillEpidemic Intelligence Service, Division of Scientific Education and Professional Development Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
L A SizemoreTennessee Department of Health,Nashville, Tennessee,USA.
M RicklesTennessee Department of Health,Nashville, Tennessee,USA.
K C CooperKnox County Health Department,Knoxville, Tennessee,USA.
C M BueckerChattanooga-Hamilton County Health Department,Chattanooga, Tennessee,USA.
H L MullinsSullivan County Regional Health Department,Kingsport, Tennessee,USA.
M G HofmeisterEpidemic Intelligence Service, Division of Scientific Education and Professional Development Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
W E AbaraEpidemic Intelligence Service, Division of Scientific Education and Professional Development Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
M A FosterDivision of Viral Hepatitis,Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
A K AsherDivision of Viral Hepatitis,Centers for Disease Control and Prevention,Atlanta, Georgia,USA.
W SchaffnerDepartment of Health Policy,Vanderbilt University Medical Center,Nashville,Tennessee,USA.
J R DunnTennessee Department of Health,Nashville, Tennessee,USA.
T F JonesTennessee Department of Health,Nashville, Tennessee,USA.
C WesterTennessee Department of Health,Nashville, Tennessee,USA.
Tennessee Department of Health · USCenters for Disease Control and Prevention · USVanderbilt University Medical Center · USEpidemic Intelligence Service · USKnox County Schools · USRegional Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To understand increasing rates of hepatitis C virus (HCV) infection in Tennessee, we conducted testing, risk factor analysis and a nested case-control study among persons who use drugs. During June-October 2016, HCV testing with risk factor assessment was conducted in sexually transmitted disease clinics, family planning clinics and an addiction treatment facility in eastern Tennessee; data were analysed by using multivariable logistic regression. A nested case-control study was conducted to assess drug-using risks and behaviours among persons who reported intranasal or injection drug use (IDU). Of 4753 persons tested, 397 (8.4%) were HCV-antibody positive. HCV infection was significantly associated with a history of both intranasal and IDU (adjusted odds ratio (aOR) 35.4, 95% confidence interval (CI) 24.1-51.9), IDU alone (aOR 52.7, CI 25.3-109.9), intranasal drug use alone (aOR 2.6, CI 1.8-3.9) and incarceration (aOR 2.7, CI 2.0-3.8). By 4 October 2016, 574 persons with a reported history of drug use; 63 (11%) were interviewed further. Of 31 persons who used both intranasal and injection drugs, 26 (84%) reported previous intranasal drug use, occurring 1-18 years (median 5.5 years) before their first IDU. Our findings provide evidence that reported IDU, intranasal drug use and incarceration are independent indicators of risk for past or present HCV infection in the study population.

Indexed as

AdolescentAdultAgedCase-Control StudiesDemographyFemaleHepatitis CHumansMaleMiddle AgedPrevalenceRisk FactorsSexually Transmitted DiseasesTennesseehealth statisticsHepatitis C viruspublic healthrisk factor analysis

Identifiers

PMID29429421
PMCPMC9134524
OpenAlexW2787260682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.